I Derm Pharma oral small molecule

I Derm Pharma is developing a proprietary, first-in-class oral small molecule therapy for the treatment of psoriasis and other autoimmune inflammatory skin diseases. The drug targets a novel, undisclosed pathway within the local skin's inflammatory cascade, allowing for the modulation of inflammation without compromising the systemic immune system. This approach is designed to offer enhanced safety and low toxicity while maintaining high efficacy, positioning it as a potential alternative to both existing oral therapies with limited efficacy and costly injectable biologics. The company was co-founded by Prof. Eli Sprecher, a leading expert in dermatology.